Table 3.
SF-36 scores at study entry and their changes over time
| SF-36 domains | Baseline score, median (range) | Patients with marginal changes (≥5–<10) during FU, n (%) | Patients with clear improvement (≥10) during FU, n (%) | Patients with score >50 at the end of the FU, n (%) |
|---|---|---|---|---|
| PF, median (range) | 75 (5–100) | 5 (10.8) | 18 (39.1) | 31 (67.3) |
| RoP, median (range) | 50 (0–100) | 0 | 10 (21.7) | 19 (41.3) |
| BP, median (range) | 51 (12–100) | 7 (15.2) | 11 (23.9) | 21 (45.6) |
| GH, median (range) | 46 (5–92) | 4 (8.6) | 12 (26.0) | 13 (28.2) |
| VT, median (range) | 45 (5–90) | 5 (10.8) | 15 (32.6) | 14 (30.4) |
| SF, median (range) | 62 (12–100) | 0 | 14 (30.4) | 22 (47.8) |
| RE, median (range) | 33 (0–100) | 0 | 11 (23.9) | 24 (52.1) |
| MH, median (range) | 52 (20–100) | 6 (13.0) | 10 (21.7) | 29 (63.0) |
| PCS score, median (range) | 41 (5–65) | NA | 14 (33.3)* | 12 (26.0) |
| MCS score, median (range) | 39.5 (23–60) | NA | 20 (43.4)* | 6 (13.0) |
Note:
*
Significant improvement is defined as an increase ≥5 points from baseline.
Abbreviations: SF-36, Short-Form 36; FU, follow-up; PF, physical functioning; RoP, role limitations related to physical problems; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role limitations related to emotional problems; MH, mental health; PCS, physical component summary; MCS, mental component summary; NA, not applicable.